141 related articles for article (PubMed ID: 8082692)
1. Spontaneous nitric oxide release accounts for the potent pharmacological actions of FK409.
Kita Y; Hirasawa Y; Maeda K; Nishio M; Yoshida K
Eur J Pharmacol; 1994 May; 257(1-2):123-30. PubMed ID: 8082692
[TBL] [Abstract][Full Text] [Related]
2. FR144420, a novel, slow, nitric oxide-releasing agent.
Kita Y; Ohkubo K; Hirasawa Y; Katayama Y; Ohno M; Nishino S; Kato M; Yoshida K
Eur J Pharmacol; 1995 Mar; 275(2):125-30. PubMed ID: 7796846
[TBL] [Abstract][Full Text] [Related]
3. Antiplatelet activities of FK409, a new spontaneous NO releaser.
Kita Y; Hirasawa Y; Yoshida K; Maeda K
Br J Pharmacol; 1994 Oct; 113(2):385-8. PubMed ID: 7834188
[TBL] [Abstract][Full Text] [Related]
4. Comparison of hemodynamic effects of nitric oxide (NO) donors with different NO-releasing properties in rats.
Kita Y; Hirasawa Y; Kato Y; Ohkubo K; Ohno M; Nishino S; Kato M; Fukuyama S
J Cardiovasc Pharmacol; 1997 Aug; 30(2):223-8. PubMed ID: 9269950
[TBL] [Abstract][Full Text] [Related]
5. Vasorelaxant mechanism of the new vasodilator, FK409.
Isono T; Koibuchi Y; Sato N; Furuichi A; Nishii M; Yamamoto T; Mori J; Kohsaka M; Ohtsuka M
Eur J Pharmacol; 1993 Aug; 246(3):205-12. PubMed ID: 7901040
[TBL] [Abstract][Full Text] [Related]
6. Acceleration of nitric oxide (NO) release from FK409, a spontaneous NO releaser, in the presence of sulfhydryl-bearing compounds.
Fukuyama S; Hirasawa Y; Cox D; Koda S; Kita Y
Pharm Res; 1995 Dec; 12(12):1948-52. PubMed ID: 8786971
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationships of spontaneous nitric oxide releasers, FK409 and its derivatives.
Fukuyama S; Hirasawa Y; Kato Y; Nishio M; Ohno M; Nishino S; Maeda K; Kato M; Kita Y
J Pharmacol Exp Ther; 1997 Jul; 282(1):236-42. PubMed ID: 9223559
[TBL] [Abstract][Full Text] [Related]
8. Antianginal effects of FK409, a new spontaneous NO releaser.
Kita Y; Ozaki R; Sakai S; Sugimoto T; Hirasawa Y; Ohtsuka M; Senoh H; Yoshida K; Maeda K
Br J Pharmacol; 1994 Dec; 113(4):1137-40. PubMed ID: 7889266
[TBL] [Abstract][Full Text] [Related]
9. FK409, a new nitric-oxide donor, suppresses smooth muscle proliferation in the rat model of balloon angioplasty.
Seki J; Nishio M; Kato Y; Motoyama Y; Yoshida K
Atherosclerosis; 1995 Sep; 117(1):97-106. PubMed ID: 8546759
[TBL] [Abstract][Full Text] [Related]
10. Close correlation of the cardioprotective effect of FK409, a spontaneous NO releaser, with an increase in plasma cyclic GMP level.
Kita Y; Sugimoto T; Hirasawa Y; Yoshida K; Maeda K
Br J Pharmacol; 1994 Sep; 113(1):5-6. PubMed ID: 7812632
[TBL] [Abstract][Full Text] [Related]
11. The involvement of the release of nitric oxide in the pharmacological activity of the new furoxan derivative CHF 2363.
Civelli M; Giossi M; Caruso P; Razzetti R; Bergamaschi M; Bongrani S; Gasco A
Br J Pharmacol; 1996 Jun; 118(4):923-8. PubMed ID: 8799563
[TBL] [Abstract][Full Text] [Related]
12. Tolerance to the vascular effect of a novel nitric oxide-donating vasodilator, FK409.
Isono T; Sato N; Yamamoto T; Sawada T; Yamazaki S; Miura S; Furuichi A; Ozaki R; Koibuchi Y; Ohtsuka M
Eur J Pharmacol; 1994 Aug; 260(2-3):163-8. PubMed ID: 7988640
[TBL] [Abstract][Full Text] [Related]
13. Oral biological activities of spontaneous nitric oxide releasers are accounted for by their nitric oxide-releasing rates and oral absorption manners.
Kita Y; Hirasawa Y; Fukuyama S; Ohkubo K; Kato Y; Takamatsu H; Ohno M; Nishino S; Kato M; Seki J
J Pharmacol Exp Ther; 1996 Feb; 276(2):421-5. PubMed ID: 8632305
[TBL] [Abstract][Full Text] [Related]
14. Comparison of antiplatelet effects of two nitric oxide-donating agents, FR146801 and FK409.
Hirasawa Y; Kato Y; Fukuyama S; Ohno M; Nishino S; Kato M; Kita Y
Thromb Haemost; 1998 Mar; 79(3):620-4. PubMed ID: 9531052
[TBL] [Abstract][Full Text] [Related]
15. Comparison of antiplatelet effects of FK409, a spontaneous nitric oxide releaser, with those of TRK-100, a prostacyclin analogue.
Hirasawa Y; Nishio M; Maeda K; Yoshida K; Kita Y
Eur J Pharmacol; 1995 Jan; 272(1):39-43. PubMed ID: 7713147
[TBL] [Abstract][Full Text] [Related]
16. Close correlation between nitric oxide (NO) formation from NO releasers and the biological activities of these agents in rats.
Kita Y; Fukuyama S; Hirasawa Y
Jpn J Pharmacol; 1995 Sep; 69(1):69-74. PubMed ID: 8847834
[TBL] [Abstract][Full Text] [Related]
17. Renal hemodynamic and excretory responses in anesthetized rats to FK409, a novel nitric oxide donor.
Urabe K; Matsumura Y; Nishiura M; Maeda K; Morimoto S
Eur J Pharmacol; 1997 Feb; 321(2):195-200. PubMed ID: 9063688
[TBL] [Abstract][Full Text] [Related]
18. Comparison of nicorandil-induced relaxation, elevations of cyclic guanosine monophosphate and stimulation of guanylate cyclase with organic nitrate esters.
Greenberg SS; Cantor E; Ho E; Walega M
J Pharmacol Exp Ther; 1991 Sep; 258(3):1061-71. PubMed ID: 1679847
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of the vasorelaxing action of (3E)-4-ethyl-2-hydroximino-5-nitro-3-hexamide FK409, a new vasodilator isolated from microbial sources, in isolated rabbit arteries.
Shibata S; Satake N; Sato N; Matsuo M; Koibuchi Y; Hester RK
J Cardiovasc Pharmacol; 1991 Mar; 17(3):508-18. PubMed ID: 1711615
[TBL] [Abstract][Full Text] [Related]
20. Nitric oxide (NO)-releasing pathway of FK409 in the presence of sulfhydryl-bearing compounds.
Fukuyama S; Azuma T; Hirasawa Y; Morokoshi N; Akama T; Koda S; Kita Y
Pharm Res; 1996 Aug; 13(8):1238-42. PubMed ID: 8865319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
